# Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029

- Source: PR Newswire M&A
- Published: 2026-11-06T15:04:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/halozyme-reaffirms-it-projects-zero-to-minimal-impact-to-royalty-revenue-through-at-least-2035-based-on-medicare-drug-price-negotiation-program-final-rule-for-ipay-2029-302932131.html
- Canonical: https://groundlevelnews.com/story/halozyme-reaffirms-it-projects-zero-to-minimal-impact-to-royalty-reven-ecdce8/

SAN DIEGO, Nov. 6, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero to minimal royalty revenue impact based on its analysis of the final rule for the Medicare Drug Price Negotiation Program...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._